2016 spring ebm free excerpt

ISSN 2364-2351 | A 60711 |

European Biotechnology

Life Sciences and Industry Magazine Spring Edition 2016 | Volume 15 | 20 â‚Ź

Interview EC Bioeconomy Director John Bell on the vital role biotech has to play in the future circular economy

Stocks take a dive Dark times for IPOs

T P R E C EE EX

FR

Clinical trials

Diabetes

Circular Economy

Bioprocessing

What probably went wrong in the recent French trial disaster

New strategies for fighting the dangerous lifestyle disease

EC legislates the end of the wasteful throw-away society

Novel techniques and services for personalised healthcare

MORE PREDICTIVE MORE HUMAN APRIL SYMPOSIA Advanced preclinical mouse models for Immunology, Oncology & Infectious Disease

Setting the standard in genetically engineered & precision research mouse models

Norway, Sweden, France, The Netherlands, & Germany LEARN MORE: TACONIC.COM/EU-SPRING

EU: +45 70 23 04 05 INFO@TACONIC.COM TACONIC.COM

ContEntS

European Biotechnology | Spring Edition | Vol. 15 | 2016

FREE EXCERPT

covEr story

InsIght EuropE

rEgIonal nEws

6

I MS Health provides first-ever data analysis on biologics-biosimilar competition in Europe

38 northern Europe:

Sweden, Denmark, Finland,

and Norway

8

Failed French Phase I trial on FAAH blocker casts involved CRo in a poor light

40 Western Europe:

France, Belgium, The Netherlands

and the UK

10 EU’s high-level expert group praises FP7; EMA expands conflict of interest policy to management board; New IMI call targets challenges with Big Data and Ebola

44 Central Europe:

Austria, Germany and Switzerland

12 European Commission again delays political decision on novel genetic breeding methods; Heard in Brussels: Circular economy – why talks keep on going around in circles

48 Eastern Europe:

Hungary, Poland, Latvia,

Lithuania and Slovakia

46 Southern Europe: Italy, Spain, Portugal, Malta, Croatia and Slovenia

scIEncE & tEchnology

Economy

56 Interview: John Bell, Director of Bioeconomy, DG Research & Innovation, European Commission

Surviving the turmoil on capital markets

20 I P Conference in Life Sciences: Exploring patentability and commercialisation strategies for Big Data innovations

70 E uropeans lead largest-ever DNA forensics programme

Equity markets have been under siege for months, with macro economic effects and sector-specific issues braking trading on both sides of the Atlantic.

But there are good reasons to remain cautiously optimistic despite the fall in IPOs. Cash is still available, and promising new treatments are coming thick and fast. So there’s hope that even if firms have to wait to go public, they’ll now be better able to cross the funding Valley of Death that has claimed so many young biotechs in the past.

22 IP Flash; Boost for microbiome companies

14

72 T he gloves are off: Battle on the CRISPR front

sErvIcE

23 Update on clinical trials 28 EMA News

73 N ews from partner associations: SBA, BIO Deutschland, DIA, EBN, EDMA

29 Analyst commentary 79 Biopeople 30 Euro Biotech Stocks 32 S tart-up story: Immunethep, Cantanhede, Portugal

80 Events 81 Company index 82 Encore

IMPRInt European Biotechnology (ISSN 2364-2351) is published quarterly by: BIOCOM AG, Lützowstr. 33–36, D-10785 Berlin, Germany, Tel.: +49-30-264921-0, Fax: +49-30-264921-11, Email: service@eurobiotechnews.eu, Internet: www.eurobiotechnews.eu; Publisher: Andreas Mietzsch, Editorial Team: Thomas Gabrielczyk (Editor in Chief), Derrick Williams (Co-editor), Uta Mommert, Dr. Martin Laqua, Julie Colthorpe, Dr. Bernd Kaltwaßer; Advertising: Oliver Schnell, +49-30-2649-2145, Christian Böhm, +49-30-2649-2149, Andreas Macht, +49-30-2649-2154; Distribution: Marcus Laschke, +49-30-2649-2148; Graphic Design: Michaela Reblin; Production editor: Benjamin Röbig; Printed at: Königsdruck, Berlin; European Biotechnology Life Sciences & Industry Magazine is only regularly available through subscription at BIOCOM AG. Annual subscription fees: € 80.00, Students € 40.00 (subject to proof of enrolment). Prices include VAT, postage & packaging. Ordered subscriptions can be cancelled within two weeks directly at BIOCOM AG. The subscription is initially valid for one year. Subscriptions will be renewed automatically for one more year, respectively, unless they are cancelled at least six weeks before the date of expiry. Failures of delivery which BIOCOM AG is not responsible for do not entitle the subscriber to delivery or reimbursement of pre-paid fees. Seat of court is Berlin, Germany. As regards contents: individually named articles are published within the sole responsibility of their respective authors. All material published is protected by copyright. No article or part thereof may be reproduced in any way or processed, copied and proliferated by electronic means without the prior written consent of the publisher. Supplement: Swiss Biotech Association, Cover Photo: © magann/fotolia.com. ® BIOCOM is a registered trademark of BIOCOM AG, Berlin, Germany.

Picture: magann/fotolia.com

4

ContEntS

European Biotechnology | Spring Edition | Vol. 15 | 2016

FREE EXCERPT

dIabEtEs

cIrcular Economy

EdItorIal

the Big Picture

The latest approaches Unhealthy lifestyles are making diabetes one of the greatest plagues of the new century. Although prevention is preferable to treatment, there’s no question that the market for innovative new approaches in the sector is expanding for developers, and a lot of money is at stake. EuroBiotEch provides an overview of the latest ideas and products from biotechnology.

50

34

Can Europe stop the flood of waste?

Even as natural resources start running low, the amount of waste we produce is peaking. EU policymakers are working on ways to escape from the unsustainable paradigm of a throw-away society.

And one of the biggest open questions is how much biotech will be needed to make their vision a reality.

Pictures: Matic Štojs, fotolia.com (right), Novo Nordisk (left), IDT Biologika (bottom)

SPECIAL Bioprocessing

Crashing oil prices, finite resources, mountains of waste and growing threats like diabetes are challenging stock exchanges, the environment, healthcare systems and job markets.

UK researchers expect the projected spread of diabetes – from currently 382 million people worldwide to 592 million by 2035 – to almost double treatment costs. And that’s not all.

They also say the lifestyle disease will massively decrease productivity and employment opportunities. Our editor Martin Laqua looks at strategies in the pipeline for treating the lifestyle disease (p. 34).

Cheap oil and global competition for access to scarce raw materials are also encouraging volatility on stock markets, and that's having a major effect on biotech performance, as Bernd Kaltwaßer reports on p. 14.

And those scarce resources are having an impact on another vital discussion.

Last December, the European Commission laid the groundwork on a strategy for ending the throw-away society and switching to a circular economy. But experts are concerned that the plan will fall short (see p. 50).

With so many global problems to be solved, Europeans will have to improve cooperation worldwide instead of fostering isolationalistic trends such as closing EU borders to refugees or thinking of a possible BREXIT. Only collaboration can help, and biotech can be part of a solution.

61 Intro: Mastering more patient-centric bioprocessing – allogenic versus autologous CAR-T cell therapies 64 Advertorial: Next biomanufacturing hub 66 Analytical technologies: highly automated protein characterisation

Thomas Gabrielczyk Editor-in-Chief

5

InSIght EuropE

European Biotechnology | Spring Edition | Vol. 15 | 2016

FREE EXCERPT

GMO invasion agri-BioteCH novel biotech breeding methods are challenging the existing regulations on gMos. While genetically engineered crops usually contain snippets of DnA from foreign organisms, novel techniques such as gene editing are able to design products that do not carry foreign genes. In fact, crops made by techniques, which enzymatically introduce targeted DnA cuts instead of using non-targeted radiation for the same purpose, can’t be distinguished from breeds created by traditional random mutagenesis.

Experts from the uS Department of Agriculture (uSDA) have already established a case-by-case regulatory pathway for such breeds. As long as the product does not differ from conventionally-bred crops, the regulatory authority exempts them from gMo review, providing a much cheaper pathway to market approval. In gMo-hostile Europe, legislators have so far delayed a political solution to the pressing problem even though a scientific analysis from 2012 said there was no difference between plants created by random and targeted mutagenesis. the European Commission’s plans to close the legal loophole by providing a novel gMo definition, have been shifted twice since last June. In mid-December, the Commission announced it will present its solution at the end of March. however, Finland, germany, Ireland, Spain, Sweden and the uK have already made their decisions. According to Shawna Mcgregor, spokesmen at the uS company Cibus Inc, these national authorities decided that its herbicide-tolerant “oDM canola” is definitely no gMo. “the competent authorities concluded that the rapeseed varieties in question did not come under the scope of Directive 2001/18,” confirmed McGregor. However, field trials, which Cibus had started in the uK in 2012 and in Sweden, have been put on hold. European plant researchers at EpSo recently stressed that research, industry and farmers urgently need legal clarification concerning the application of novel breeding technologies. 

Heard in Brussels Going round in circles matches the prinBrussels I am too ciples of the circudepressed to write lar economy action about the UK playing plan published at the silly buggers with the end of 2015 which EU and the negative has the intention to impact on science, change production so let’s look at someprocesses, consumpthing positive for Eution, waste managerope instead – the dement and turning velopment of circular waste into a resource economy opportuni– all areas where bioties for biotechnolotechnology can work gy. Let’s start by exits magic. plaining what t he Most areas of biocircular economy is, Claire skentelBery technology can conbefore you say ‘eh?’

Secretary General of the Eurotribute; food proand read something pean Biotechnology Network d u c t i o n, e n e r g y, else. Its aim is to enenvironmental monitoring, industrial sure that the value of products, mateprocesses etc etc, there’s room for innorials and resources is maintained in the vation and economic return across the economy for as long as possible, and board. A quick look at the BBI workthe generation of waste minimised. plan for 2016 highlights the commerIt essentially looks at production, cial opportunities for biotech perfectconsumption and waste as a bigger ly, with topics including extraction of picture, something the EU is genuorganic material from waste water for inely able to do, with the aim to benfeedstock, novel fermentation of bioefit citizens and the ecosystem of Eucompounds, advanced biomaterials rope in the long term. We can expect for packaging, recovering and re-using a combined set of actions that include enzymes in industrial processes … the regulation and economic developlist goes on, read it yourself you lazy ment incentives and this is genuinely beggars. an opportunity for biotechnology to The circular economy makes sense find new applications and create glofor Europe – the world is demonstratbal economic opportunities. Because ing on a daily basis how economies Europe follows a long term approach, and society suffer when the environit might be faster than many other rement is degraded. There will certaingions in the world, which are more rely be plenty of moaning about Brusactive than proactive, in creating scisels stopping you throwing your fridge entific and business capabilities. in the pond or making you dry your European biotechnology is already hair with a straight banana. However, working towards economic return from if we take the 20-year, “isn’t the water circular economy actions, look at the clean”, view rather than the 5-minute, Bio-Based Industries (BBI) Joint Un“it’s my human right to leave the fridge dertaking, a public private partnerdoor open”, view – we will hopefully ship leveraging €2.7 billion of private find that Europe is still habitable and investment and €975 million EU funds we have thriving industries that will to target sustainable biomass, biorehelp make that happen.  fineries and market development. This

Picture: EBN

12

RuBRik

European Biotechnology | Spring Edition | Vol. 15 | 2016

Pictures: xxx

14

CoVER StoRy

European Biotechnology | Spring Edition | Vol. 15 | 2016

FREE EXCERPT

IPOs: The times they are a-changin’ Early January saw a few indicators that stock markets might deliver some solid biotech results in 2016, even if it isn’t destined to be a hallmark year for the industry.

But then, in the weeks that followed, the situation began to deteriorate. Now it looks like European biotech companies might have to start coming to terms with a closing IPO window.

industry sentiment

E

Source: Credit Suisse First Boston (2005–3/2015), BIOCOM AG, Data kindly provided by DZ Bank AG (2015–2016 YTD); Picture: rolffimages/fotolia.com (left)

quity markets overall have been under siege for many months.

Macro economic effects like dwindling oil prices, imploding Chinese stock quotes and closer scrutiny of Russia’s economic powerbase have been braking trading on both sides of the Atlantic. And sector-specific concerns like drug-pricing debates and looming patent expiries haven’t helped ameliorate the situation for biotech firms.

Will 2016 see sector carnage?

At first glance the outlook looks pretty grim. Between 1 January and mid-February, the Nasdaq Biotechnology index

(NBi) lost about 25% of its value. the first month of 2016 was also the thirdworst monthly performance in the measure’s history. Comprising some 190 biotech stocks traded on the uS-based technology stock exchange, the index lost every inch of ground it had gained in 2015. it’s starting to look as if the biotech sector’s three-year deluge of public market debuts, with dozens of companies raising billions of dollars in funding, is now rapidly grinding to a halt. And not just newcomers are seeing falls in value.

“Even for the highest-quality companies, there is less demand than there was a few months ago for iPos,” Ziad Bakri, a healthcare analyst at mutual fund firm T.

Rowe Price, told the Wall Street Journal. “it’s very tough.” there have been several early warning signs that the path to going public is growing increasingly rocky. the overall number of iPos in the uS has fallen, while more and more companies have pulled the plug on plans to take the step.

Citing adverse market conditions, the first biotech companies have decided against pursuing a listing at Euronext or AiM as well in the second half of 2015. January of 2016 was the first month without a single iPo in the uS in more than five … ›› Read the full story in the printed issue.

Biotech vs. major industrial index’s stock price performance using S&P sector indices 2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

3/2015

2015

2016 YTD

Energy 29%

telecom 32%

Energy 32%

Biotech 10%

it 60%

Cons Disc 26%

Biotech 22%

Biotech 38%

Biotech 74%

Biotech 33%

Biotech 7%

Cons Disc 9%

telecom 9%

Biotech 18%

Energy 22%

Material 20%

Cons Stap –18%

Materials 45%

industrials 24%

utilities 15%

Financials 26%

Cons Disc 41%

utilities 24%

Healthcare 6%

Healthcare 5%

utilities 8%

utilities 13%

Cons Disc 17%

utilities 16%

Healthcare –24%

Cons Disc 39%

Materials 20%

Cons Stap 11%

Cons Disc 22%

Healthcare 39%

Healthcare 23%

Cons Disc 4%

it 4%

Cons Stap 2%

Healthcare 5%

utilities 17%

it 16%

utilities –32%

S&P 500 23%

Energy 18%

Healthcare 10%

Healthcare 15%

industrials 38%

it 18%

telecom 0%

Cons Stap 4%

industrial –1%

Financials 4%

Financials 16%

Cons Stap 12%

telecom –34%

industrials 17%

S&P 500 13%

Cons Disc 4%

S&P 500 13%

Financials 33%

Financials 13%

Cons Stap 0%

Biotech 4%

Energy –3%

S&P 500 3%

Materials 16%

industrials 10%

Cons Disc –35%

Healthcare 17%

telecom 12%

Energy 3%

it 13%

S&P 500 30%

Cons Stap 13%

S&P 500 0%

S&P 500 –1%

Materials –3%

Materials 2%

S&P 500 14%

telecom 8%

Energy –36%

Financials 15%

Financials 11%

it 1%

telecom 12%

it 26%

S&P 500 11%

Materials 0%

telecom –2%

S&P 500 –3%

Cons Stap 1%

Const Stap 12%

Healthcare 5%

S&P 500 –38%

Energy 11%

Cons Stap 11%

telecom 1%

industrials 12%

Materials 23%

Cons Disc 8%

it 0%

Financial –4%

Cons Disc –4%

it 0%

industrials 11%

S&P 500 4%

industrials –42%

Cons Stap 11%

it 9%

S&P 500 0%

Materials 12%

Cons Stap 23%

industrials 8%

industrials –2%

industrial –5%

it –4%

industrials 0%

it 8%

Biotech –3%

it –44%

utilities 7%

Biotech 2%

industrials –3%

Cons Stap 8%

Energy 22%

Materials 5%

Financials –3%

utilities –9%

Healthcare –6%

Cons Disc –7%

Healthcare 6%

Cons Disc –14%

Materials –47%

telecom 3%

utilities 1%

Materials –12%

Energy 2%

utilities 9%

telecom –2%

Energy –4%

Materials –11%

Financial –9%

telecom –9%

Biotech –3%

Financials –21%

Financials –57%

Biotech –7%

Healthcare 1%

Financials –18%

utilities –3%

telecom 6%

Energy –10%

utilities –7%

Energy –24%

Biotech –11%

15

DiaBEtES

European Biotechnology | Spring Edition | Vol. 15 | 2016

FREE EXCERPT

Taking the fight to a looming epidemic With the advance of obesity and related metabolic disorders, diabetes has become a global threat. The good news is that thanks to better access to more and better treatment options, mortality and morbidity linked to the illness are slowing. But that's just a first step. Diabetics now also want advances in managing the disease. Products from improved versions of insulin to painand stress-free delivery methods have a chance to grab a share of a market worth billions. And in the background, research groups are working on concepts for actually curing the condition.

Diabetes

›› Read the full story in the printed issue.

Picture: Novo Nordisk

34

BioEconomy

European Biotechnology | Spring Edition | Vol. 15 | 2016

FREE EXCERPT

Can Europe stop the stream of waste?

CirCular EConomy For decades now, Europeans have dreamed of creating a low-waste society

powered by an economy that copies cycles and principles found in nature. In December, the European Commission laid the foundation stone for establishing a ‘circular economy’, which aims at protecting the world’s finite resources by – among other measures – repairing products instead of throwing them away. At the moment, the strategy is focused on waste prevention. But will that be enough to meet challenges like global warming, marine debris and shortages of raw materials? ›› Read the full story in the printed issue.

Picture: Matic Štojs/fotolia.com

50

European Biotechnology | Spring Edition | Vol. 15 | 2016

Company IndEx FREE EXCERPT

3B pharmaceuticals GmbH (GER). . . . . . . . . . . . 44 abbVie Inc. (USa) . . . . . . . . . . . . . . . . . . . . 23, 29 abivax aB (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 ablynx BV (B) . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 abzena plc (UK) . . . . . . . . . . . . . . . . . . . . . . . . . 41 aCE BioSciences a/S (dK) . . . . . . . . . . . . . . . . . 28 aclaris Therapeutics (USa) . . . . . . . . . . . . . . . . . 18 adaptimmune Ltd. (UK) . . . . . . . . . . . . . . . . . . . 29 Affimed GmbH (GER) . . . . . . . . . . . . . . . . . . 44, 79 albumedix (dK) . . . . . . . . . . . . . . . . . . . . . . . . . 38 almirall S. a. (ES) . . . . . . . . . . . . . . . . . . . . . . . . 46 alphabet (USa). . . . . . . . . . . . . . . . . . . . . . . . . . 20 aLpLa (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 angle plc (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . 40 apeiron Biologics (aT) . . . . . . . . . . . . . . . . . . . . 45 apogenix aG (GER) . . . . . . . . . . . . . . . . . . . . . . 19 apple (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 arGEn-x B.V. (nL) . . . . . . . . . . . . . . . . . . . . . . . 23 aristi Biotech BV . . . . . . . . . . . . . . . . . . . . . . . . 41 asia pte Ltd (SG) . . . . . . . . . . . . . . . . . . . . . . . . . 47 aSSoBIoTEC (IT) . . . . . . . . . . . . . . . . . . . . . . . . 46 astraZeneca aB (SE/UK) . . . . . . . . . . 23, 24, 28,41 auria (FI) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 avantium Life Sciences BV (nL) . . . . . . . . . . . . . 40 axxam Spa (IT). . . . . . . . . . . . . . . . . . . . . . . . . . 46 B.T.m. Savjetovanje d.o.o. (HR) . . . . . . . . . . . . . 47 BaSF (GER) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45 Bavarian nordic a/S (dK) . . . . . . . . . . . . . . . . . . 39 Bayer aG (GER) . . . . . . . . . . . . . . . . . . . . . . 28, 45 BC platforms (CH) . . . . . . . . . . . . . . . . . . . . . . . 39 Bellerophon Therapeutics (USa) . . . . . . . . . . . . . 18 Bial-portela & Ca Sa (pT) . . . . . . . . . . . . . . . . . . . 8 Bio products Laboratory (UK) . . . . . . . . . . . . . . . 28 Bio-on S.p.a. (IT) . . . . . . . . . . . . . . . . . . . . . . . . 47 Biocartis Sa (CH) . . . . . . . . . . . . . . . . . . . . . . . . 41 BIoCom aG (GER) . . . . . . . . . . . . . . . . 18, 57, 65 Biodesix Inc. (USa). . . . . . . . . . . . . . . . . . . . . . . 40 Bioglobe GmbH (GER) . . . . . . . . . . . . . . . . . 70, 71 Biomarin Europe Ltd. (UK) . . . . . . . . . . . . . . . . . 28 Biomedica 2016 (GER) . . . . . . . . . . . . . . . . . . . . . 9 Bionor pharma aSa (n) . . . . . . . . . . . . . . . . . . . 24 Biontis GmbH (GER). . . . . . . . . . . . . . . . . . . . . . 70 Biophytis SaS (F) . . . . . . . . . . . . . . . . . . . . . . . . 18 Biotrial (F). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Boehmert & Boehmert (GER) . . . . . . . . . . . . 17, 72 Boehringer Ingelheim (GER) . . . . . . . . . . 24, 36, 37 Brain aG (GER) . . . . . . . . . . . . . . . . . . . . . . . 19, 45 Bristol-myers Squibb (USa) . . . . . . . . . . . . . 24, 28 Cambridge Innovation Capital (UK) . . . . . . . . . . 40 Cassiopea Spa (IT) . . . . . . . . . . . . . . . . . . . . . . . 29 Celgene Europe Ltd. (UK) . . . . . . . . . . . . . . . . . . 24 ChemChina . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45 CmS Hasche Sigle (GER) . . . . . . . . . . . . . . . . . . 22 Coca-Cola (USa) . . . . . . . . . . . . . . . . . . . . . 40, 54 Crispr Therapeutics (CH) . . . . . . . . . . . . . . . . . . . 45 Cytos Biotechnology aG (CH). . . . . . . . . . . . . . . 18 danone (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 designeRx (USa) . . . . . . . . . . . . . . . . . . . . . . . . 28 dIa Europe (CH) . . . . . . . . . . . . . . . . . . . . . . .Cp4 Easyfairs Switzerland GmbH (GER) . . . . . . . . . . . 53 Editas medicine (USa) . . . . . . . . . . . . . . . . . . . . 19 Elanix Therapeutics (CH). . . . . . . . . . . . . . . . . . . 18 Eli Lilly & Co Ltd (USa) . . . . . . . . . . . . . 35, 36, 37 Eli Lilly nederland . . . . . . . . . . . . . . . . . . . . . . . 28 Eligo Bioscience (F) . . . . . . . . . . . . . . . . . . . . . . 22 Enterome (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Epistem Ltd (UK) . . . . . . . . . . . . . . . . . . . . . . . . . 79 Eppendorf aG/Bioprocess Center Europe (GER) . 60 Eridania Sadam S.p.a. (IT) . . . . . . . . . . . . . . . . . 47

Erydel Spa (IT) . . . . . . . . . . . . . . . . . . . . . . . . . . 46 EuropaBio/European Biotech Week (B) . . . . . . . . 13 European Biotechnology network (B) . . . . . . . . . 21 Evaxion Biotech (dK) . . . . . . . . . . . . . . . . . . . . . 39 Evgen pharma (UK). . . . . . . . . . . . . . . . . . . . . . . 18 FIT Biotech oyi plc (FI). . . . . . . . . . . . . . . . . . . . 18 Frost & Sullivan (UK) . . . . . . . . . . . . . . . . . . . . . 94 FUJIFILm diosynth Biotechnologies (USa) . . . . . 67 Galapagos nV (B) . . . . . . . . . . . . . . . . . . 23, 24, 29 Geneuro S.a. (CH) . . . . . . . . . . . . . . . . . . . . . . . 23 Genmab a/S (dK) . . . . . . . . . . . . . . . . . . . . . . . . 29 Genomics plc (UK) . . . . . . . . . . . . . . . . . . . . . . . 79 genoway S. a. (F) . . . . . . . . . . . . . . . . . . . . . . . . 41 GF Biochemicals (IT/nL). . . . . . . . . . . . . . . . . . . 46 Gilead Ltd. (USa) . . . . . . . . . . . . . . . . . . 23, 25 29 GlaxoSmithKline (UK) . . . . . . . . . . . . . . . . . 20, 41 Glycomar (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . 38 HealthCap (SE) . . . . . . . . . . . . . . . . . . . . . . . . . . 39 High-Tech Gründerfonds management (GER) . . . 55 HTG molecular diagnostics . . . . . . . . . . . . . . . . 18 IBm Corp. (USa) . . . . . . . . . . . . . . . . . . . . . . . . 20 Illumina Inc. (USa) . . . . . . . . . . . . . . . . . . . . . . . 94 Immunethep Sa (pT) . . . . . . . . . . . . . . . . . . . . . . 32 Immunocore Ltd. (UK) . . . . . . . . . . . . . . . . . . . . 23 Immunovia aB (SE) . . . . . . . . . . . . . . . . . . . . . . . 18 Impasara Ltd. (UK) . . . . . . . . . . . . . . . . . . . . . . . 28 Imperial Innovations Group plc (UK) . . . . . . . . . 40 Inivata Ltd. (UK) . . . . . . . . . . . . . . . . . . . . . . . . . 40 Innovate UK . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 Innovation norway . . . . . . . . . . . . . . . . . . . . . . . 38 Inotek pharmaceuticals (USa). . . . . . . . . . . . . . . 18 Invivoscribe Technologies (USa) . . . . . . . . . . . . . 25 Ipsen (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 Jaguar animal Health (USa) . . . . . . . . . . . . . . . . 18 Janssen Biotech Inc. (USa) . . . . . . . . . . . . 8, 22, 29 Johnson & Johnson (USa) . . . . . . . . . . . . 37, 40, 41 Karcinolys S.a.S. (F) . . . . . . . . . . . . . . . 28 Kempharm (USa) . . . . . . . . . . . . . . . . . . . . . . . . 18 KLm (nL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 Kuros Biosciences (CH) . . . . . . . . . . . . . . . . . . . 79 Kuros Biosurgery aG (CH) . . . . . . . . . . . . . . . . . 18 Laboratorios Farmaceuticos Rovi S.a. (ES) . . . . . 29 Larix aS (dK) . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 LEo pharma a/S (dK) . . . . . . . . . . . . . . . . . . . . . 24 Life Science austria LISa (aT) . . . . . . . . . . . . . . . 33 Life Science Baltics 2016 (LT) . . . . . . . . . . . . 42, 43 Lufthansa aG (GER) . . . . . . . . . . . . . . . . . . . . . . 39 Lysogene SaS (F) . . . . . . . . . . . . . . . . . . . . . . . . . 28 m+W Central Europe GmbH (GER) . . . . . . . . . . 69 maaT pharma (F) . . . . . . . . . . . . . . . . . . . . . . . . 22 maikowski & ninnemann (GER) . . . . . . . . . . 26, 27 mcKinsey & Co. (GER) . . . . . . . . . . . . . . . . . . . . 51 medimmune Ltd (UK) . . . . . . . . . . . . . . . . . . . . . 23 medivir aB (SE). . . . . . . . . . . . . . . . . . . . . . . . . . 39 merck & Co. (USa) . . . . . . . . . . . . . . . . . 35, 36, 37 merck KGaa (GER) . . . . . . . . . . . . . . . . . 25, 37, 41 merck Sharp & dohme Ltd (USa) . . . . . . . . . . . . 28 microa aS (n) . . . . . . . . . . . . . . . . . . . . . . . . . . 38 micropharma . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 miltenyi Biotech GmbH (GER) . . . . . . . . . . . . . . 28 mitim Srl. (IT) . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 mitsui Global Investment (Jp) . . . . . . . . . . . . . . . 40 mLm medical Labs GmbH (GER) . . . . . . . . . . . . . 7 mologen aG (GER) . . . . . . . . . . . . . . . . . . . . . . . 24 monsanto (USa) . . . . . . . . . . . . . . . . . . . . . . . . . 45 morphoSys aG (GER) . . . . . . . . . . . . . . . . . . . . . 28 motif Bio plc (UK) . . . . . . . . . . . . . . . . . . . . . . . 18 mytomorrows (nL) . . . . . . . . . . . . . . . . . . . . . . . 20 nanoReproaG (GER) . . . . . . . . . . . . . . . . . . . . . 47

nestle S.a. (CH) . . . . . . . . . . . . . . . . . . . . . . . . . 45 newron pharmaceuticals S.p.a. (IT) . . . . . . . . . . 46 nexvet Biopharma (USa) . . . . . . . . . . . . . . . . . . 18 nitin Lifesciences Ltd (Ind) . . . . . . . . . . . . . . . . 38 nordic nanovector aS (n) . . . . . . . . . . . . . . . . . 18 northwest E-Health (UK) . . . . . . . . . . . . . . . . . . 20 novacyt Sa (F) . . . . . . . . . . . . . . . . . . . . . . . . . . 40 novartis aG (CH) . . . . . . . . . . . . . . . . . . 22, 25, 44 novo nordisk a/S (dK) . . . . . . . . . . . . . . . . . . . . 28 novozymes a/S (dK) . . . . . . . . . . . . . . . . . . 29, 38 octreopharm GmbH (GER) . . . . . . . . . . . . . . . . 44 onTarget Chemistry (SE) . . . . . . . . . . . . . . . . . . . 38 onxeo S.a. (dK) . . . . . . . . . . . . . . . . . . . . . . . . . 39 opGen (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 opIS s.r.l. (IT) . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 oSE pharma Sa (F) . . . . . . . . . . . . . . . . . . . . . . . 24 oxford nanopore Technologies Ltd. (UK) . . . . . . 94 perkinElmer (LaS) Germany GmbH . . . . 63, 66, 68 Pfizer (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 pharmamar (ES) . . . . . . . . . . . . . . . . . . . . . . . . . 47 philogen S.p.a. (IT) . . . . . . . . . . . . . . . . . . . . . . . 23 poli Group Holding S.r.l. (nL) . . . . . . . . . . . . . . . 46 polichem S.a. (CH) . . . . . . . . . . . . . . . . . . . . . . . 46 polpharma biologics (pL) . . . . . . . . . . . . . . . 64, 65 porta Systems aG (GER) . . . . . . . . . . . . . . . . . . . 18 poxel Sa (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 prasinotech Ltd. (UK) . . . . . . . . . . . . . . . . . . . . . 38 primer disign Ltd. (UK). . . . . . . . . . . . . . . . . . . . 40 proFibrix BV (nL) . . . . . . . . . . . . . . . . . . . . . . . . 28 pronutria Biosciences (USa) . . . . . . . . . . . . . . . . 45 prothena Corp. plc (IRL) . . . . . . . . . . . . . . . . . . . 24 protix BV (nL) . . . . . . . . . . . . . . . . . . . . . . . . . . 41 Qiagen nV (GER) . . . . . . . . . . . . . . . . . . . . . 29, 71 Qualcomm (USa) . . . . . . . . . . . . . . . . . . . . . . . . 20 Recipharm aB (n). . . . . . . . . . . . . . . . . . . . . . . . 38 Relief Therametrics Sa (CH) . . . . . . . . . . . . . . . . 18 Riboxx GmbH (GER) . . . . . . . . . . . . . . . . . . . . . 41 Rx Securities (UK) . . . . . . . . . . . . . . . . . . . . . . . . 29 S.E.C.I. Spa (IT) . . . . . . . . . . . . . . . . . . . . . . . . . 47 Sanofi SA (F) . . . . . . . . . . . . . . . . 8, 35, 36, 37, 44 SaS – Scandinavian airlines (SE) . . . . . . . . . . . 39 Scancell Holding plc. (UK) . . . . . . . . . . . . . . . . . 23 Segetis (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 Sensorion aG (CH) . . . . . . . . . . . . . . . . . . . . . . . 18 Seres Therapeutics (USa) . . . . . . . . . . . . . . . . . . 18 Servier (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Spark Therapeutics (USa) . . . . . . . . . . . . . . . . . . 18 Stora Enso Ventures oy (FI) . . . . . . . . . . . . . . . . . 39 Surface oncology (USa) . . . . . . . . . . . . . . . . . . . 44 Swiss Biotech association (CH). . Supplement, Cp3 Syngenta aG (CH) . . . . . . . . . . . . . . . . . . . . . . . 45 Taconic Biosciences (USa) . . . . . . . . . . . . . . . .Cp2 Takeda pharmaceuticals (Jp) . . . . . . . . . . . . . 22, 37 Taurus pharma GmbH (GER) . . . . . . . . . . . . . . . 46 Therametrics Holding aG (CH) . . . . . . . . . . . . . . 18 Theravectys (F) . . . . . . . . . . . . . . . . . . . . . . . . . . 28 ThermiGen LLC. (USa) . . . . . . . . . . . . . . . . . . . . 46 ThermoFisher Scientific (USA) . . . . . . . . . . . . . . 71 Threshold pharmaceuticals Inc. . . . . . . . . . . . . . 25 Tollys SaS (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 Transgene Sa (F) . . . . . . . . . . . . . . . . . . . . . . . . . 40 Vectura Group plc (UK) . . . . . . . . . . . . . . . . . . . 29 Vernalis (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Vetter pharma-Fertigung GmbH & Co.KG (GER) . 25 Viomedo (GER) . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Vossius & partner (GER) . . . . . . . . . . . . . . . . . . . 20 Woodford Investment management LLp (UK) . . . 40 ZaB Brandenburg Ec. dev. Board (GER) . . . . . . . 11 Zosano pharma (USa) . . . . . . . . . . . . . . . . . . . . 18

81

SWISS BIOTECH DAY 2016

Foto: Leonid Andronov/Fotolia.com

The leading Life Sciences Conference in Switzerland and Annual General Assembly of the Swiss Biotech Association

The Swiss Biotech Day is the leading biotechnology conference in Switzerland. Constantly growing, the 2016 event will bring together around 500 senior executives from the life science industry across Europe.

Programme highlights will be keynotes given by senior representatives of Siegfried AG and Bayer Pharma AG, as well as the presentation of the 2016 Swiss Biotech Report. Parallel sessions in the afternoon will focus on emerging biotechnology companies, publicly listed biotech companies, geographic hotspots in biotech and compliance. Additionally, there will be an exhibition and extensive partnering opportunities with one-to-one meetings.

CLUSTER

ect-specific young and inensive partner ic window. are important Biotech sectanding of the ought into ciation, where

lexakis

More information on the conference and online registration can be found at: www.swissbiotechday.ch

12 APRIL 2016 Basel Congress Center

Sponsors:

SWISS BIOTECH...

...is an alliance of four leading Biotech regions of Switzerland (Bio Alps, BioPolo Ticino, Basel Area and Greater Zurich Area). They have combined efforts to streamline interests of the national biotech sector. The SWX Swiss Exchange holds a leading position in terms of lifescience listings and offers companies from that industry – be they located in Switzerland or abroad – access to an internationally recognised financial marketplace. The initiative was co-founded by the SBA which also manages the executive by: office of Swiss Biotech.

Organised

In cooperation with:

Supporting partner:

Media Partner:

DIA 28th Annual

EuroMeeting INnovation z Do You Win by Being IN? 6-8 April 2016 | CCH | Hamburg, Germany

Your premier opportunity to learn from and collaborate with thought leaders across key health care product development stakeholder groups.

Exhibiting Opportunities Available: Join our New Global Village and interact face-to-face with 2,500+ participants, your future customers.

Visit DIAglobal.org/EM2016 today to learn moreƫ * ƫregister